Seems the NSCLC folks are starting from a tough position. Cant help thinking what would the responses be if the treatment was initiated at an earlier stage. That is when a person's immune system was more robust. Prior to the impact of cancer and drugs suppressive side effects on their immune response. It seems this is a challenge for any perspective new treatment. Kind of like attempting to resuscitate a patient when it's too late.
Ann: Encouraging Phase II TACTI-002 data reported at SITC 2020, page-11
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 37.0¢ | $186.2K | 500.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 73290 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 181396 | 15 |
View Market Depth
| Last trade - 10.10am 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |